Platelet-rich plasma for osteoarthritic knee: change of synovial biomarkers and clinical outcomes
Completed
- Conditions
- Change of synovial biomarkers and clinical outcomes in patients with Knee OA after platelet-rich plasma treatment.knee osteoarthritis, knee OA
- Registration Number
- TCTR20211108002
- Lead Sponsor
- Chulalongkorn University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
Selection criteria included knee OA according to the American College of Rheumatology (ACR), 45-85 years of age, grade 1 to 4 of radiographic knee OA according to the Kellgren-Lawrence system, body mass index (BMI) < 30, > 90-degree arc of motion, < 10-degree anatomical knee deformity in the coronal plane, and no skin lesion around the affected knee.
Exclusion Criteria
Exclusion criteria included inflammatory arthritis, previous knee surgery, knee pain with an antalgic gait, and thrombocytopenia. In addition, all recruited patients had a 2-week washing-out period for any pain killers or no non-steroidal anti-inflammatory drugs (NSAIDs), as well as joint supplements
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method synovial fluid biomarkers (inflammatory cytokines, anti-inflammatory cytokines, and growth factors) at a 6-week interval before each PRP injection of 2-cycle or 4-cycle PRP protocol until 18 weeks Level of all biomarkers using a commercial proteome cytokine array kit and reported in pg/m
- Secondary Outcome Measures
Name Time Method VAS, WOMAC, SF-12, Time up and go, 5-time sit to stand, and 3-minute walk test At 6 weeks, 12 weeks, 18 weeks, 6 months and 1 year VAS, WOMAC and SF-12 are evaluated using patient's report on the questionnaires. Time up and go, 5-time sit to stand and 3-minute walk tests are evaluated by clinical evaluators